-
1
-
-
0017236348
-
Bestatin, an inhibitor of aminopeptidase B, produced by actinomycetes
-
Umezawa H, Aoyagi T, Suda H, Hamada M, Takeuchi T. Bestatin, an inhibitor of aminopeptidase B, produced by actinomycetes. J Antibiot 1976;29:97-9.
-
(1976)
J. Antibiot.
, vol.29
, pp. 97-99
-
-
Umezawa, H.1
Aoyagi, T.2
Suda, H.3
Hamada, M.4
Takeuchi, T.5
-
2
-
-
0018963797
-
Mitogenic effect of bestatin on lymphocytes
-
Ishizuka M, Saito K, Sugiyama Y, Takeuchi T, Umezawa H. Mitogenic effect of bestatin on lymphocytes. J Antibiot 1980;33:653-62.
-
(1980)
J. Antibiot.
, vol.33
, pp. 653-662
-
-
Ishizuka, M.1
Saito, K.2
Sugiyama, Y.3
Takeuchi, T.4
Umezawa, H.5
-
3
-
-
0020577840
-
Identification and properties of the cell membrane bound leucine aminopeptidase interacting with the potential immunostimulant and chemotherapeutic agent bestatin
-
Leyhausen G, Schuster DK, Vaith P, Zahn RK, Umezawa H, Falke D, et al. Identification and properties of the cell membrane bound leucine aminopeptidase interacting with the potential immunostimulant and chemotherapeutic agent bestatin. Biochem Pharmacol 1983;32:1051-7.
-
(1983)
Biochem. Pharmacol.
, vol.32
, pp. 1051-1057
-
-
Leyhausen, G.1
Schuster, D.K.2
Vaith, P.3
Zahn, R.K.4
Umezawa, H.5
Falke, D.6
-
4
-
-
0019950846
-
Properties and specificity of binding sites for the immunomodulator bestatin on the surface of mammalian cells
-
Müller WE, Schuster DK, Zahn RK, Maidhof A, Leyhausen G, Falke D, et al. Properties and specificity of binding sites for the immunomodulator bestatin on the surface of mammalian cells. Int J Immunopharmacol 1982; 4:393-400.
-
(1982)
Int. J. Immunopharmacol.
, vol.4
, pp. 393-400
-
-
Müller, W.E.1
Schuster, D.K.2
Zahn, R.K.3
Maidhof, A.4
Leyhausen, G.5
Falke, D.6
-
5
-
-
0024518875
-
Human myeloid plasma membrane glycoprotein CD13 (gp150) is identical to aminopeptidase N
-
Look AT, Ashmun RA, Shapiro LH, Peiper SC. Human myeloid plasma membrane glycoprotein CD13 (gp150) is identical to aminopeptidase N. J Clin Invest 1989;83:1299-307.
-
(1989)
J. Clin. Invest.
, vol.83
, pp. 1299-1307
-
-
Look, A.T.1
Ashmun, R.A.2
Shapiro, L.H.3
Peiper, S.C.4
-
6
-
-
0025019614
-
Metalloprotease activity of CD13/aminopeptidase N on the surface of human myeloid cells
-
Ashmun RA, Look AT. Metalloprotease activity of CD13/aminopeptidase N on the surface of human myeloid cells. Blood 1990;75:462-9.
-
(1990)
Blood
, vol.75
, pp. 462-469
-
-
Ashmun, R.A.1
Look, A.T.2
-
7
-
-
0027479013
-
Aminopeptidase: Structure and function
-
Taylar A. Aminopeptidase: structure and function. FASEB J 1993;7:290-8.
-
(1993)
FASEB J.
, vol.7
, pp. 290-298
-
-
Taylar, A.1
-
8
-
-
0027244148
-
Hematopoietic differentiation antigens that are membrane-associated enzymes: Cutting is the key!
-
Shipp MA, Look AT. Hematopoietic differentiation antigens that are membrane-associated enzymes: cutting is the key! Blood 1993;82:1052-70.
-
(1993)
Blood
, vol.82
, pp. 1052-1070
-
-
Shipp, M.A.1
Look, A.T.2
-
9
-
-
0027103632
-
The significance of aminopeptidase and haematopoietic cell differentiation
-
Razak K, Newland AC. The significance of aminopeptidase and haematopoietic cell differentiation. Blood Rev 1992;6:243-50.
-
(1992)
Blood Rev.
, vol.6
, pp. 243-250
-
-
Razak, K.1
Newland, A.C.2
-
10
-
-
0025770253
-
Leucine aminopeptidase: Bestatin inhibition and a model for enzyme-catalyzed peptide hydrolysis
-
Burley SK, David PR, Lipscomb WN. Leucine aminopeptidase: bestatin inhibition and a model for enzyme-catalyzed peptide hydrolysis. Proc Natl Acad Sci U S A 1991;88:6916-20.
-
(1991)
Proc. Natl. Acad. Sci. U. S. A.
, vol.88
, pp. 6916-6920
-
-
Burley, S.K.1
David, P.R.2
Lipscomb, W.N.3
-
12
-
-
0027195127
-
Role of aminopeptidase N (CD13) in tumor-cell invasion and extracellular matrix degradation
-
Saiki I, Fujii H, Yoneda J, Abe F, Nakajima M, Tsuruo T, et al. Role of aminopeptidase N (CD13) in tumor-cell invasion and extracellular matrix degradation. Int J Cancer 1993;54:137-43.
-
(1993)
Int. J. Cancer
, vol.54
, pp. 137-143
-
-
Saiki, I.1
Fujii, H.2
Yoneda, J.3
Abe, F.4
Nakajima, M.5
Tsuruo, T.6
-
13
-
-
0030048006
-
Inhibition of tumor cell invasion and matrix degradation by aminopeptidase inhibitor
-
Fujii H, Nakajima M, Aoyagi T, Tsuruo T. Inhibition of tumor cell invasion and matrix degradation by aminopeptidase inhibitor. Biol Pharm Bull 1996; 19:6-10.
-
(1996)
Biol. Pharm. Bull.
, vol.19
, pp. 6-10
-
-
Fujii, H.1
Nakajima, M.2
Aoyagi, T.3
Tsuruo, T.4
-
14
-
-
0033950895
-
Aminopeptidase is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis
-
Pasqualini R, Koivunen E, Kain R, Lahdenranta J, Sakamoto M, Stryhn A, et al. Aminopeptidase is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 2000;60:722-7.
-
(2000)
Cancer Res.
, vol.60
, pp. 722-727
-
-
Pasqualini, R.1
Koivunen, E.2
Kain, R.3
Lahdenranta, J.4
Sakamoto, M.5
Stryhn, A.6
-
15
-
-
0035254206
-
CD13/APN is activated by angiogenic signals and is essential for capillary tube formation
-
Bhagwat SV, Lahdenranta J, Giordano R, Arap W, Pasqualini R, Shapiro LH. CD13/APN is activated by angiogenic signals and is essential for capillary tube formation. Blood 2001;97:652-9.
-
(2001)
Blood
, vol.97
, pp. 652-659
-
-
Bhagwat, S.V.1
Lahdenranta, J.2
Giordano, R.3
Arap, W.4
Pasqualini, R.5
Shapiro, L.H.6
-
16
-
-
0029781804
-
Induction of apoptosis by ubenimex (Bestatin) in human non-small-cell lung cancer cell lines
-
Ezawa K, Minota K, Dobashi K. Induction of apoptosis by ubenimex (Bestatin) in human non-small-cell lung cancer cell lines. Biomed Pharmacother 1996;50:283-9.
-
(1996)
Biomed. Pharmacother
, vol.50
, pp. 283-289
-
-
Ezawa, K.1
Minota, K.2
Dobashi, K.3
-
17
-
-
0036161112
-
Aminopeptidase N is involved in cell motility and angiogenesis: Its clinical significance in human colon cancer
-
Hashida H, Takabayashi A, Kanai M, Adachi M, Kondo K, Kohno N, et al. Aminopeptidase N is involved in cell motility and angiogenesis: its clinical significance in human colon cancer. Gastroenterology 2002;122:376-86.
-
(2002)
Gastroenterology
, vol.122
, pp. 376-386
-
-
Hashida, H.1
Takabayashi, A.2
Kanai, M.3
Adachi, M.4
Kondo, K.5
Kohno, N.6
-
18
-
-
0021358471
-
Effect of bestatin on syngeneic tumors in mice
-
Abe F, Shibuya K, Uchida M, Takahashi K, Horinishi H, Matsuda A, et al. Effect of bestatin on syngeneic tumors in mice. Gann 1984;75:89-94.
-
(1984)
Gann
, vol.75
, pp. 89-94
-
-
Abe, F.1
Shibuya, K.2
Uchida, M.3
Takahashi, K.4
Horinishi, H.5
Matsuda, A.6
-
19
-
-
0022503903
-
Immunomodulatory and therapeutic properties of bestatin in mice
-
Talmadge JE, Lenz BF, Pennington R, Long C, Phillips H, Schneider M, et al. Immunomodulatory and therapeutic properties of bestatin in mice. Cancer Res 1986;46:4505-10.
-
(1986)
Cancer Res.
, vol.46
, pp. 4505-4510
-
-
Talmadge, J.E.1
Lenz, B.F.2
Pennington, R.3
Long, C.4
Phillips, H.5
Schneider, M.6
-
20
-
-
0029563918
-
Aminopeptidase inhibitor ubenimex inhibits the growth of human choriocarcinoma in nude mice through its direct cytostatic activity
-
Ino K, Goto S, Nomura S, Isobe K, Nawa A, Okamoto T, et al. Aminopeptidase inhibitor ubenimex inhibits the growth of human choriocarcinoma in nude mice through its direct cytostatic activity. Anticancer Res 1995; 15:2081-7.
-
(1995)
Anticancer Res.
, vol.15
, pp. 2081-2087
-
-
Ino, K.1
Goto, S.2
Nomura, S.3
Isobe, K.4
Nawa, A.5
Okamoto, T.6
-
21
-
-
0022552509
-
Immunotherapy with bestatin for acute nonlymphocytic leukemia in adults
-
Ohta K, Kurita S, Yamada K, Masaoka T, Uzuka Y, Ogawa N. Immunotherapy with bestatin for acute nonlymphocytic leukemia in adults. Cancer Immunol Immunother 1986;23:5-10.
-
(1986)
Cancer Immunol. Immunother
, vol.23
, pp. 5-10
-
-
Ohta, K.1
Kurita, S.2
Yamada, K.3
Masaoka, T.4
Uzuka, Y.5
Ogawa, N.6
-
22
-
-
0027321230
-
Ubenimex in the treatment of acute nonlymphocytic leukemia in adults
-
Urabe A, Mutoh Y, Mizoguchi H, Takaku F, Ogawa N. Ubenimex in the treatment of acute nonlymphocytic leukemia in adults. Ann Hematol 1993; 67:63-6.
-
(1993)
Ann. Hematol.
, vol.67
, pp. 63-66
-
-
Urabe, A.1
Mutoh, Y.2
Mizoguchi, H.3
Takaku, F.4
Ogawa, N.5
-
23
-
-
0030451274
-
Monocyte activation by an oral immunomodulator bestatin in lymhoma patients following autologous bone marrow transplantation
-
Ino K, Bierman PJ, Varney ML, Heimann DG, Kuszynski CA, Walker SA, et al. Monocyte activation by an oral immunomodulator bestatin in lymhoma patients following autologous bone marrow transplantation. Cancer Immunol Immunother 1996;43:206-12.
-
(1996)
Cancer Immunol. Immunother
, vol.43
, pp. 206-212
-
-
Ino, K.1
Bierman, P.J.2
Varney, M.L.3
Heimann, D.G.4
Kuszynski, C.A.5
Walker, S.A.6
-
24
-
-
0025115634
-
Bestatin in resected lung cancer a randomized clinical trial
-
Yasumitsu T, Ohshima S, Nakano N, Kotake Y, Tominaga S. Bestatin in resected lung cancer a randomized clinical trial. Acta Oncologica 1990;29: 827-31.
-
(1990)
Acta Oncologica
, vol.29
, pp. 827-831
-
-
Yasumitsu, T.1
Ohshima, S.2
Nakano, N.3
Kotake, Y.4
Tominaga, S.5
-
25
-
-
0022628932
-
A new international staging system for lung cancer
-
Mountain CF. A new international staging system for lung cancer. Chest 1986;89(4 Suppl):225S-233S.
-
(1986)
Chest
, vol.89
, Issue.4 SUPPL.
-
-
Mountain, C.F.1
-
26
-
-
0020396015
-
Toxicity and response criteria of the Eastern Cooperative Oncology Group
-
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
-
(1982)
Am. J. Clin. Oncol.
, vol.5
, pp. 649-655
-
-
Oken, M.M.1
Creech, R.H.2
Tormey, D.C.3
Horton, J.4
Davis, T.E.5
McFadden, E.T.6
-
27
-
-
0003486931
-
-
Geneva (Switzerland): World Health Organization Offset Publication No. 48
-
WHO handbook for reporting results of cancer treatment. Geneva (Switzerland): World Health Organization Offset Publication No. 48. 1979:14-21.
-
(1979)
WHO Handbook for Reporting Results of Cancer Treatment
, pp. 14-21
-
-
-
28
-
-
0019362251
-
Introduction to sample size determination and power analysis for clinical trial
-
Lachin JM. Introduction to sample size determination and power analysis for clinical trial. Control Clin Trials 1981;2:93-113.
-
(1981)
Control Clin. Trials
, vol.2
, pp. 93-113
-
-
Lachin, J.M.1
-
29
-
-
0000336139
-
Regression models and life-tables
-
Cox DR. Regression models and life-tables. J Roy Statist Soc Ser B 1972; 34:187-220.
-
(1972)
J. Roy Statist. Soc. Ser. B
, vol.34
, pp. 187-220
-
-
Cox, D.R.1
-
30
-
-
0019416738
-
Survival of patients surgically treated for stage I lung cancer
-
Williams DE, Pairolero PC, Davis CS, Bernatz PE, Payne WS, Taylor WF, et al. Survival of patients surgically treated for stage I lung cancer. J Thorac Cardiovasc Surg 1981;82:70-6.
-
(1981)
J. Thorac. Cardiovasc. Surg.
, vol.82
, pp. 70-76
-
-
Williams, D.E.1
Pairolero, P.C.2
Davis, C.S.3
Bernatz, P.E.4
Payne, W.S.5
Taylor, W.F.6
-
31
-
-
0021749274
-
Perioperative blood transfusion adversely affects prognosis after resection of stage I (subset N0) non-oat cell lung cancer
-
Tartter PI, Burrows L, Kirschner P. Perioperative blood transfusion adversely affects prognosis after resection of stage I (subset N0) non-oat cell lung cancer. J Thorac Cardiovasc Surg 1984;88:659-62.
-
(1984)
J. Thorac. Cardiovasc. Surg.
, vol.88
, pp. 659-662
-
-
Tartter, P.I.1
Burrows, L.2
Kirschner, P.3
-
32
-
-
0027949292
-
A placebo-controlled randomized double-blind study of adjuvant intrapleural BCG in patients with resected T1N0, T1N1, or T2N0 squamous cell carcinoma, adenocarcinoma, or large cell carcinoma of the lung
-
Gail MH. A placebo-controlled randomized double-blind study of adjuvant intrapleural BCG in patients with resected T1N0, T1N1, or T2N0 squamous cell carcinoma, adenocarcinoma, or large cell carcinoma of the lung. Chest 1994;106:287S-92S.
-
(1994)
Chest
, vol.106
-
-
Gail, M.H.1
-
33
-
-
0017287037
-
Regional immunotherapy of lung cancer with intrapleural BCG
-
McKneally MF, Maver CM, Kausel HW. Regional immunotherapy of lung cancer with intrapleural BCG. Lancet 1976;1:377-9.
-
(1976)
Lancet
, vol.1
, pp. 377-379
-
-
McKneally, M.F.1
Maver, C.M.2
Kausel, H.W.3
-
34
-
-
0027301691
-
Is T factor of the TNM staging system a predominant prognostic factor in pathologic stage I non-small-cell lung cancer?
-
Ichinose Y, Hara N, Ohta M, Yano T, Maeda K, Asoh H, et al. Is T factor of the TNM staging system a predominant prognostic factor in pathologic stage I non-small-cell lung cancer? J Thorac Cardiovasc Surg 1993;106: 90-4.
-
(1993)
J. Thorac. Cardiovasc. Surg.
, vol.106
, pp. 90-94
-
-
Ichinose, Y.1
Hara, N.2
Ohta, M.3
Yano, T.4
Maeda, K.5
Asoh, H.6
-
35
-
-
0028811996
-
Incidence of local recurrence and second primary tumors in resected stage I lung cancer
-
Martini N, Bains MS, Burt ME, Zakowski MF, McCormack P, Rusch VW, et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 1995;109:120-9.
-
(1995)
J. Thorac. Cardiovasc. Surg.
, vol.109
, pp. 120-129
-
-
Martini, N.1
Bains, M.S.2
Burt, M.E.3
Zakowski, M.F.4
McCormack, P.5
Rusch, V.W.6
-
36
-
-
0033570968
-
Conventional clinicopathologic prognoses factors in surgically resected nonsmall cell lung carcinoma
-
Suzuki K, Nagai K, Yoshida J, Nishimura M, Takahashi K, Yokose T, et al. Conventional clinicopathologic prognoses factors in surgically resected nonsmall cell lung carcinoma. Cancer 1999;86:1976-84.
-
(1999)
Cancer
, vol.86
, pp. 1976-1984
-
-
Suzuki, K.1
Nagai, K.2
Yoshida, J.3
Nishimura, M.4
Takahashi, K.5
Yokose, T.6
-
37
-
-
0025264310
-
Cancer recurrence after resection: T1 N0 non-small cell lung cancer
-
Thomas P, Rubinstein LV. Cancer recurrence after resection: T1 N0 non-small cell lung cancer. Ann Thorac Surg 1990;49:242-7.
-
(1990)
Ann. Thorac. Surg.
, vol.49
, pp. 242-247
-
-
Thomas, P.1
Rubinstein, L.V.2
-
39
-
-
0033046028
-
Induction of apoptosis by bestatin (ubenimex) in human leukemic cell lines
-
Sekine K, Fujii H, Abe F. Induction of apoptosis by bestatin (ubenimex) in human leukemic cell lines. Leukemia 1999;13:729-34.
-
(1999)
Leukemia
, vol.13
, pp. 729-734
-
-
Sekine, K.1
Fujii, H.2
Abe, F.3
-
40
-
-
0033961824
-
Modification of the amino terminus of a class II epitope confers degradation by CD13 on dendritic cells and enhances presentation to T cells
-
Dong X, An B, Salvucci Kierstead L, Storkus WJ, Amoscato AA, Salter RD. Modification of the amino terminus of a class II epitope confers degradation by CD13 on dendritic cells and enhances presentation to T cells. J Immunol 2000;164:129-35.
-
(2000)
J. Immunol.
, vol.164
, pp. 129-135
-
-
Dong, X.1
An, B.2
Salvucci Kierstead, L.3
Storkus, W.J.4
Amoscato, A.A.5
Salter, R.D.6
-
41
-
-
0035906224
-
Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer
-
Lippman SM, Lee JJ, Karp DD, Vokes EE, Benner SE, Goodman GE, et al. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst 2001;93:605-18.
-
(2001)
J. Natl. Cancer Inst.
, vol.93
, pp. 605-618
-
-
Lippman, S.M.1
Lee, J.J.2
Karp, D.D.3
Vokes, E.E.4
Benner, S.E.5
Goodman, G.E.6
-
42
-
-
0018598923
-
Restoration of impaired immune function of aged animals by chronic bestatin treatment
-
Bruley-Rosset M, Florentin I, Kiger N, Schulz J, Mathé G. Restoration of impaired immune function of aged animals by chronic bestatin treatment. Immunology 1979;38:75-83.
-
(1979)
Immunology
, vol.38
, pp. 75-83
-
-
Bruley-Rosset, M.1
Florentin, I.2
Kiger, N.3
Schulz, J.4
Mathé, G.5
-
43
-
-
0022547774
-
The effect of ubenimex of N-methyl-N′-nitro-N-nitrosoguanidine-induced stomach tumor in rats
-
Ebihara K, Abe F, Yamashita T, Shibuya K, Hayashi E, Takahashi K, et al. The effect of ubenimex of N-methyl-N′-nitro-N-nitrosoguanidine-induced stomach tumor in rats. J Antibiot (Tokyo) 1986;39:966-70.
-
(1986)
J. Antibiot. (Tokyo)
, vol.39
, pp. 966-970
-
-
Ebihara, K.1
Abe, F.2
Yamashita, T.3
Shibuya, K.4
Hayashi, E.5
Takahashi, K.6
|